ArticleIranian journal of pharmaceutical research : IJPR
Renoprotective Effects of
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phytochemical Analysis of Moroccan Mercurialis annua L. and Its Nephroprotective Activity: Evidence Supporting Traditional Renal Uses.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cyclophosphamide (CP), a widely used chemotherapeutic agent, induces significant nephrotoxicity through oxidative stress and inflammation. Objectives: This study aimed to investigate the renoprotective effects of Methods: Mice were randomly divided into four groups: Control, AJE only, CP only, and AJE + CP. Treatments were administered for 14 days. Kidney function, oxidative stress markers, inflammatory cytokines, and histopathological changes were evaluated. Results: CP administration significantly increased serum urea and creatinine levels, enhanced lipid peroxidation, and reduced antioxidant enzyme activities. Histopathological analysis revealed marked renal damage. Pretreatment with AJE significantly attenuated these alterations by restoring renal function markers (P < 0.01), reducing oxidative stress (P < 0.001), and enhancing antioxidant defenses (P < 0.001). Compared with the CP-only group, AJE also significantly reduced levels of pro-inflammatory cytokines (P < 0.001). Conclusions: AJE exerts significant protective effects against CP-induced nephrotoxicity through dual antioxidant and anti-inflammatory mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.